Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of diabetic and non-diabetic patients treated with either linezolid or vancomycin for MRSA-nosocomial pneumonia in the modified intent to treat (MITT) population

From: The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycin

  Diabetic Patients (N = 183) Non-diabetic Patients (N = 265)
Characteristic Linezolid N = 87 Vancomycin N = 96 Linezolid N = 137 Vancomycin N = 128
Age (y), mean (SD) *** 67.1 (13.0) 69.8 (12.8) 58.2 (19.8) 56.1 (19.3)
Male Sex, n (%) 57 (65.5) 55 (57.3) 94 (68.6) 88 (68.8)
Race, n (%)
 White 59 (67.8) 60 (62.5) 97 (70.8) 92 (71.9)
 Black 11 (12.6) 15 (15.6) 14 (10.2) 16 (12.5)
 Asian 12 (13.8) 17 (17.7) 20 (14.6) 16 (12.5)
 Other 5 (5.7) 4 (4.2) 6 (4.4) 4 (3.1)
Treatment duration (days), mean (SD) 9.7 (4.1) 9.1 (4.9) 10.1 (3.8) 10.0 (4.1)
Baseline blood glucose (mg/dl), na/mean (SD) 83/176.3 (116.7) 91/167.8 (123.5) 129/164.7 (152.7) 121/174.9 (158.9)
Bacteremia, n (%)
 Yes 6 (6.9) 10 (10.4) 9 (6.6) 14 (10.9)
 No 78 (89.7) 85 (88.5) 116 (84.7) 110 (85.9)
 Unknown 3 (3.4) 1 (1.0) 12 (8.8) 4 (3.1)
Insulin at Baseline n (%) 58 (66.7) 74 (77.1) N/A N/A
Ventilated at baseline, n (%) 58 (66.7) 70 (72.9) 95 (69.3) 93 (72.7)
APACHE Score, n (%) ***
  < 20 50 (57.5) 52 (54.2) 91 (66.4) 87 (68.0)
  ≥ 20 36 (41.4) 42 (43.8) 43 (31.4) 39 (30.5)
 Unknown 1 (1.1) 2 (2.1) 3 (2.2) 2 (1.6)
CPIS score, na/mean (SD) Baseline 56/9.6 (2.2) 63/9.5 (2.1) 89/9.5 (2.1) 91/9.2 (2.4)
Chest x-ray, n (%)b
 Unilateral 20 (23.0) 29 (30.2) 39 (28.5) 50 (39.1)
 Bilateral 65 (74.7) 67 (69.8) 98 (71.5) 78 (60.9)
 Pleural effusion, n (%) 42 (48.3) 38 (39.6) 63 (46.0) 58 (45.3)
Weight (kg), na/mean (SD) *** 87/85.6 (26.8) 96/79.2 (22.4) 137/73.2 (18.0) 127/76.2 (20.4)
Comorbidities, n (%)
 Cardiac *** 58 (66.7) 69 (71.9) 73 (53.3) 68 (53.1)
 Hepatobiliary 13 (14.9) 10 (10.4) 21 (15.3) 21 (16.4)
 Gastrointestinal *** 57 (65.5) 56 (58.3) 71 (51.8) 63 (49.2)
 Neoplastic 8 (9.2) 13 (13.5) 12 (8.8) 12 (9.4)
 Renal/Urinary *** 40 (46.0) 53 (55.2) 43 (31.4) 41 (32.0)
 Pulmonary 65 (74.7) 67 (69.8) 87 (63.5) 87 (68.0)
 Vascular *** 38 (43.7) 37 (38.5) 38 (27.7) 41 (32.0)
Baseline pathogens, n (%)
 MRSA only 53 (60.9) 62 (64.6) 66 (48.2) 66 (51.6)
 MRSA + other Gr (+) 6 (6.9) 9 (9.4) 16 (11.7) 9 (7.0)
 MRSA + other Gr (-) 19 (21.8) 18 (18.8) 41 (29.9) 38 (29.7)
MRSA+ other Gr (+) and Gr (-) 5 (5.7) 3 (3.1) 8 (5.8) 10 (7.8)
 MRSA + anaerobes 0 1 (1.0) 0 1 (0.8)
 MRSA + fungal 4 (4.6) 3 (3.1) 6 (4.4) 4 (3.1)
Baseline Vancomycin MICs, n (%)
  ≤ 0.5 7 (8.0) 2 (2.1) 10 (7.3) 12 (9.4)
 1 63 (72.4) 75 (78.1) 105 (76.6) 93 (72.7)
 2 7 (8.0) 7 (7.3) 6 (4.4) 11 (8.6)
 4 0 1 (1.0) 0 1 (0.8)
 unknown 10 (11.5) 11 (11.5) 16 (11.7) 11 (8.6)
  1. Abbreviations: CPIS clinical pulmonary infection score, MRSA methicillin-resistant S. aureus, SD standard deviation
  2. aDenotes the number of patients with available data when different than the group total
  3. bAmong diabetic patients treated with linezolid, 1 had a normal chest x-ray and one had unknown chest x-ray findings
  4. *P < 0.05 for linezolid vs vancomycin treated diabetic patients; ** P < 0.05 for linezolid vs vancomycin treated non-diabetic patients; *** P < 0.05 for diabetic patients vs. non-diabetic patients